Top Tech Companies (2,070)
Don't see your company?
Create a company profile
Spinogenix is developing neurorestorative therapeutics.
Inform Diagnostics, previously known as Miraca Life Sciences serves more than 5,500 patients each day, providing expert pathology services in the fields of dermatopathology, breast pathology, GI pathology, hematology/oncology pathology, and urologic pathology. Additionally, Miraca provides health IT consulting services, and has helped hundreds of practices with programs such as MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012. In November 2017, Miraca Life Sciences was acquired by Avista Capital Partners. As a leader in anatomic pathology, Inform Diagnostics combines the rigor of an academic medical institution with the innovative spirit of a technology company. By working for Inform Diagnostics, you will have the opportunity to contribute alongside top multidisciplinary talented professionals, who are dedicated to meeting the needs of our clinician clients and their patients. You will work in a state-of-the-art environment with cutting-edge tools, breakthrough technologies and with world-renowned thought leaders. The company utilizes a forward-thinking business model seeking to make a profound difference in the quality of care for patients.
Stability Biologics, a provider of human tissue and bone graft products
Emerald Heath Pharmaceuticals is a biotech company developing novel therapies for neurodegenerative and autoimmune diseases. Including multiple sclerosis, systemic sclerosis (a form of scleroderma), Parkinson's disease and Huntington's disease. References/Sources: - National Multiple Sclerosis Society - Parkinson’s Foundation - Huntington’s Disease Society of America - Scleroderma Foundation - Global Multiple Sclerosis Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 To 2025 Research and Markets Report - Scleroderma Diagnostics and Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024 Transparency Market Research Report - Parkinson's Disease Therapeutics Market Global Industry Analysis Size, Share, Growth ,Trends, and Forecasts, 2017 To 2025 Transparency Market Research Report - Opportunity Analyzer: Huntington's Disease Opportunity Analysis and Forecast to 2024 Research and Markets Report
CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases.
Nano-based therapeutics for existing and emerging diseases
Working to solve complex problems in taste receptor biology and employ new therapeutic modalities to treating eating disorders and obesity.
VakSea is a biotechnology company that makes immune-boosting protein to immunize and protect shrimp from the disease.
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
Understand your genome. Help cure diseases. Own your data. Powered by blockchain.
Aether’s mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.
MavenView use public and privately-licensed data to support strategic decisions in competitive strategy and commercialization.
At Sony Biotechnology, our flow cytometry and imaging products reflect our full commitment to produce and support high quality, innovative products to support advanced biomedical research. Founded in 1995, we are based in San Jose, California with affiliate offices in Japan, China and Europe. Innovation Research and Development as well as engineering teams are based in Japan. Their innovative approaches and technical know-how is incorporated into our product platforms has been recognized in patents as well as numerous technology and design awards. For example, to improve stability, our systems allow direct monitoring of particle flow status using technology originally developed for the Blu-ray disk that delivers error free performance while operating at very high speed. In conventional flow cytometers, this accuracy largely depends on skillful operators. To deliver very low noise electronics, our systems incorporate technologies that have brought pure, true sound to music. This Sony know-how reduces signal noise from the electric circuit currents to achieve very low noise electronics so that rogue signal noise does not get in the way of delivering accurate results to scientists. Importantly, our innovations also come from looking beyond the conventional made possible by constant sensing and deep study of advanced technologies for superior solutions to customer challenges. Our use of microfluidics and spectral analysis are two examples of this innovative approach to product design and development.
Encysive Pharmaceuticals develops synthetic and small molecule compounds to address medical needs worldwide.
Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines.
Biotechnology startup developing automated species identification technologies for AgTech, BioTech, and Environmental monitoring sectors.
Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture. Led by a team of expert geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St. Paul, Minnesota.
The Revolutionary New Way to Support YOUR Health
Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the goal of advancing promising laboratory discoveries into patients. Pluristyx has a developed a proprietary footprint-free method to generate induced Pluripotent Stem Cells (iPSCs) from clinically-relevant starting material. Pluristyx iPSCs are manufactured at scale and cryopreserved at high-density in a Ready-to-Differentiate® (RTD®) format that can be immediately thawed for downstream differentiation without the need for additional expansion. Pluristyx also provides the consulting and process development support required to incorporate these RTD®-iPSCs into existing workflows to accelerate product development and clinical translation. In October, 2022 Pluristyx announced a merger with panCELLa. Pluristyx today offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.
Vascugen is a biotechnology company developing regenerative medicine for treatment of intractable vascular diseases.
